MRKMerck & Co.
Merck & Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. 10-K, Item 1
- Employees
- 75,000
- Headquarters
- Rahway, NJ
- CEO
- Robert M. Davis
- Next results
- around Feb 2, 2027
Key numbers
Latest fiscal year, with ten years behind eachWhat changed
10-K filed Feb 24, 2026 against Feb 25, 2025| Area | What changed | Source |
|---|---|---|
| Risk factors | 12 new paragraphs, nothing like them in the previous 10-K | 10-K Item 1A |
| Receivables growing faster than revenue | Receivables +14.6% vs revenue +1.3% (+13.3 pts) | 10-K · XBRL |
| Cash from operations lower than net income | Cash from operations $16.5B vs net income $18.3B (FY ending 2025-12-31) | 10-K · XBRL |
| Accounting checks | 9 other checks clear, 2 worth a look | 10-K · XBRL |
| Insiders | No open-market buys in the last 90 days | Form 4 |
| Filings | 3 in the last 30 days | EDGAR |
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
What's new, in their words
10-K filed Feb 24, 2026Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-25. Quoted as filed.
The Company faces continued pricing pressure with respect to its products in the public and private sectors. The Company faces continued pricing pressure globally and, particularly in mature markets, from managed care organizations, government agencies and programs that could negatively affect the Company’s sales
10-K, Item 1A
Accounting checks
latest 10-K9 of 11 clear 2 worth a look. Checks, not verdicts.
- !Receivables growing faster than revenueReceivables +14.6% vs revenue +1.3% (+13.3 pts)
- !Cash from operations lower than net incomeCash from operations $16.5B vs net income $18.3B (FY ending 2025-12-31)
- ✓Inventory +9.0% vs revenue +1.3% (+7.7 pts)
- ✓Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
- ✓No statement of substantial doubt about going concern
- ✓No 8-K item 4.02 in the last 2 years
- ✓No NT 10-K or NT 10-Q in the last 2 years
- ✓The same matters as last year: U.S. Rebate Accruals - Medicaid, Managed Care and Medicare Part D; PricewaterhouseCoopers LLP; Florham Park, New Jersey; February 24, 2026
- ✓No sentence in the 10-K concludes that controls were not effective because of a material weakness
- ✓No 8-K item 2.06 in the last 2 years
- ✓No 8-K item 1.03 in the last 2 years
In the last 30 days
All filings →- Nov 4, 202610-Q Quarterly report (10-Q) period ended Sep 30, 2026
- Oct 29, 20268-K Quarterly results 8-K item 2.02
- Oct 13, 20268-K Director or officer change 8-K item 5.02
About Merck & Co.
10-K, Feb 24, 2026Merck & Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders.
- Headquarters
- Rahway, NJ
- Country
- United States
- Reports in
- USD
- Listed on
- NYSE
- Fiscal year ends
- December 31
- Last results
- Oct 29, 2026
- Incorporated in
- NJ
Employees, at the top of the page: "As of December 31, 2025, the Company had approximately 75,000 employees worldwide, including approximately 30,000 people in the U" (10-K). Address and exchange: SEC's company file.
Permanent link, kept if the ticker changes: /c/sec:0000310158 (SEC's CIK).
Work on MRK in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/MRK/export.csv") into a cell.